Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

Phase 2

Withdrawn

Conditions: Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD

Interventions: Drug: Deferasirox

First Posted Date: 2013-09-24

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01948817

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Phase 3

Completed

Conditions: Age-related Macular Degeneration
Choroidal Neovascularization

Interventions: Drug: Ranibizumab 0.5mg

First Posted Date: 2013-09-24

Last Posted Date: 2017-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 650

Registration Number: NCT01948830

Locations: 🇬🇧
Novartis Investigative Site, Sunderland, United Kingdom

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Conditions: Non-small Cell Lung Cancer (NSCLC)

First Posted Date: 2013-09-20

Last Posted Date: 2020-11-03

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01947608

Locations: 🇺🇸
Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
🇺🇸
Stanford University, Stanford, California, United States

and more 25 locations

Safety and Efficacy of Fingolimod in MS Patients in China

Phase 3

Withdrawn

Conditions: Multiple Sclerosis (Relapsing Remitting)

Interventions: Drug: Placebo (6mos) + open label fingolimod (6 mos)
Drug: fingolimod

First Posted Date: 2013-09-12

Last Posted Date: 2017-04-21

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01941004

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Phase 1

Completed

Conditions: Recurrent Glioblastoma Multiforme

Interventions: Drug: buparlisib
Drug: carboplatin
Drug: lomustine
Drug: placebo

First Posted Date: 2013-09-04

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT01934361

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 3 locations

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

Phase 2

Completed

Conditions: Single Umbilical Cord Blood Transplantation
Non-myeloablative Conditioning
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia

Interventions: Drug: HSC835

First Posted Date: 2013-08-28

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT01930162

Locations: 🇺🇸
Novartis Investigative Site, Minneapolis, Minnesota, United States

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Phase 2

Terminated

Conditions: Pemphigus Vulgaris

Interventions: Drug: Placebo
Drug: VAY736

First Posted Date: 2013-08-28

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT01930175

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Metastatic Solid Tumors

Interventions: Drug: BGJ398
Drug: BYL719

First Posted Date: 2013-08-26

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT01928459

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa, Florida, United States
🇺🇸
University of Michigan Comprehensive Cancer Center SC, Ann Arbor, Michigan, United States
🇺🇸
Karmanos Cancer Institute Dept of Onc, Detroit, Michigan, United States

and more 5 locations

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

Phase 2

Completed

Conditions: Sporadic Inclusion Body Myositis

Interventions: Drug: BYM338/bimagrumab
Drug: Placebo

First Posted Date: 2013-08-19

Last Posted Date: 2017-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 251

Registration Number: NCT01925209

Locations: 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: buparlisib
Drug: alpelisib

First Posted Date: 2013-08-15

Last Posted Date: 2018-09-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 340

Registration Number: NCT01923168

Locations: 🇺🇸
Emory University School of Medicine/Winship Cancer Institute SC, Atlanta, Georgia, United States
🇺🇸
Los Angeles Hematology/Oncology Medical Group Onc Dept., Los Angeles, California, United States
🇺🇸
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy